Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus VIGPODER.
PARADIONE vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
100 mg orally three times daily; maximum 600 mg/day.
150 mg orally twice daily with or without food.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category C
Category C
Anticonvulsant
Anticonvulsant